Pear Therapeutics, Inc. recently announced the first participant enrolled in an open-label, decentralized clinical trial…
Arboretum_JDJuly 13, 2020
Pear Therapeutics, Inc., the leader in Prescription Digital Therapeutics (PDTs), announced today that it has…
Arboretum_JDJanuary 8, 2020
Pear Therapeutics, Inc. today announced the first patient dosed in part II of the first…
Arboretum_JDDecember 17, 2019
Pear Therapeutics, Inc. announced today that it has entered into an agreement with Ironwood Pharmaceuticals,…
Arboretum_JDOctober 30, 2019
Pear Therapeutics today announced the filing of a submission to the U.S. Food and Drug…
Arboretum_JDJuly 18, 2019
Pear Therapeutics, Inc. recently announced the start of a feasibility study for a prescription digital…
Arboretum_JDMay 8, 2019
Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced today the US commercial launch…
Arboretum_JDJanuary 9, 2019
Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that it has successfully…
Arboretum_JDJanuary 4, 2019
Sandoz Inc., a division of Novartis, and Pear Therapeutics, Inc., the leader in prescription digital…
Arboretum_JDDecember 10, 2018
